Last reviewed · How we verify
Epinephrin 0.01
Epinephrin 0.01 is a Catecholamine; adrenergic agonist Small molecule drug developed by Kasr El Aini Hospital. It is currently FDA-approved for Anaphylaxis, Cardiac arrest (asystole, pulseless electrical activity, ventricular fibrillation), Severe hypotension. Also known as: adrenaline.
Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation.
Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation. Used for Anaphylaxis, Cardiac arrest (asystole, pulseless electrical activity, ventricular fibrillation), Severe hypotension.
At a glance
| Generic name | Epinephrin 0.01 |
|---|---|
| Also known as | adrenaline |
| Sponsor | Kasr El Aini Hospital |
| Drug class | Catecholamine; adrenergic agonist |
| Target | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine; Cardiovascular; Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Epinephrine binds to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors on target tissues. This activation increases cardiac contractility and heart rate (beta-1), causes vasoconstriction (alpha-1), and promotes bronchial smooth muscle relaxation (beta-2). The 0.01 concentration indicates a dilute formulation typically used for local hemostasis or mild systemic effects.
Approved indications
- Anaphylaxis
- Cardiac arrest (asystole, pulseless electrical activity, ventricular fibrillation)
- Severe hypotension
- Bronchospasm
- Local hemostasis during surgery
Common side effects
- Tachycardia
- Hypertension
- Tremor
- Anxiety
- Headache
- Arrhythmias
- Myocardial ischemia
Key clinical trials
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE2)
- Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal (NA)
- Hemodynamic Effects of Different Vasoconstrictors in Mandibular Exodontia (PHASE4)
- Reducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPR (NA)
- Photobiomodulation for Controlling Pre-Local Anesthetic Injection Pain (NA)
- Analgesic Effects of Extraoral Ultrasound Block of Mandibular Nerve for the Extraction of Lower Third Molars (NA)
- Evaluation of the Effects of Pre-operative Deflazacort on Post-operative Pain, Edema and Trismus (PHASE4)
- Evaluation of the Effects of Irrigation of the Extraction Socket With Rifamycine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epinephrin 0.01 CI brief — competitive landscape report
- Epinephrin 0.01 updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI
Frequently asked questions about Epinephrin 0.01
What is Epinephrin 0.01?
How does Epinephrin 0.01 work?
What is Epinephrin 0.01 used for?
Who makes Epinephrin 0.01?
Is Epinephrin 0.01 also known as anything else?
What drug class is Epinephrin 0.01 in?
What development phase is Epinephrin 0.01 in?
What are the side effects of Epinephrin 0.01?
What does Epinephrin 0.01 target?
Related
- Drug class: All Catecholamine; adrenergic agonist drugs
- Target: All drugs targeting Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
- Manufacturer: Kasr El Aini Hospital — full pipeline
- Therapeutic area: All drugs in Emergency Medicine; Cardiovascular; Anesthesia
- Indication: Drugs for Anaphylaxis
- Indication: Drugs for Cardiac arrest (asystole, pulseless electrical activity, ventricular fibrillation)
- Indication: Drugs for Severe hypotension
- Also known as: adrenaline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing